These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 8920701)

  • 1. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children.
    Raz R; Dagan R; Gallil A; Brill G; Kassis I; Koren R
    Vaccine; 1996 Feb; 14(3):207-11. PubMed ID: 8920701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults.
    Raz R; Koren R; Bass D
    Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates.
    Yerushalmi B; Raz R; Blondheim O; Shumov E; Koren R; Dagan R
    Pediatr Infect Dis J; 1997 Jun; 16(6):587-92. PubMed ID: 9194109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines.
    Shouval D; Ilan Y; Adler R; Deepen R; Panet A; Even-Chen Z; Gorecki M; Gerlich WH
    Vaccine; 1994 Nov; 12(15):1453-9. PubMed ID: 7533967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid seroprotection against hepatitis B following the first dose of a Pre-S1/Pre-S2/S vaccine.
    Shapira MY; Zeira E; Adler R; Shouval D
    J Hepatol; 2001 Jan; 34(1):123-7. PubMed ID: 11211888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B Virus Revaccination With Standard Versus Pre-S Vaccine in Previously Immunized Patients With Celiac Disease.
    Heshin-Bekenstein M; Turner D; Shamir R; Bar-Meir M; Dagan R; Zevit N; Silbermintz A
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):400-3. PubMed ID: 25988560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen.
    Douvin C; Simon D; Charles MA; Deforges L; Bierling P; Lehner V; Budkowska A; Dhumeaux D
    Diabetes Care; 1997 Feb; 20(2):148-51. PubMed ID: 9118762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus vaccination for older adults.
    Bennett RG; Powers DC; Remsburg RE; Scheve A; Clements ML
    J Am Geriatr Soc; 1996 Jun; 44(6):699-703. PubMed ID: 8642163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparison of antibody response to different hepatitis b vaccines with and without pre-S2 antigen in children with cancer.
    Emir S; Büyükpamuk M; Akyüz C; Kutluk T; Güler E; Cağlar K
    Pediatr Hematol Oncol; 2002 Jun; 19(4):227-33. PubMed ID: 12051588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India.
    Velu V; Nandakumar S; Shanmugam S; Jadhav SS; Kulkarni PS; Thyagarajan SP
    World J Gastroenterol; 2007 Jun; 13(22):3084-9. PubMed ID: 17589924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.
    Keating GM; Noble S
    Drugs; 2003; 63(10):1021-51. PubMed ID: 12699402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
    Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety in newborns of a new recombinant hepatitis B vaccine containing the S and pre-S2 antigens.
    Soulié JC; Devillier P; Santarelli J; Goudeau A; Vermeulen P; Guellier M; Saliou P; Hillion AM; Tron F; Huchet J
    Vaccine; 1991 Aug; 9(8):545-8. PubMed ID: 1837646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B.
    Martins RM; Bensabath G; Arraes LC; Oliveira Mde L; Miguel JC; Barbosa GG; Camacho LA
    Mem Inst Oswaldo Cruz; 2004 Dec; 99(8):865-71. PubMed ID: 15761604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunogenicity and harmlessness in the newborn of a vaccine (GenHevac B) containing the antigens S and pre-S2].
    Tron F; Soulié JC; Goudeau A; Devillier P; Saliou P
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):901-5. PubMed ID: 1840243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.
    Shouval D; Roggendorf H; Roggendorf M
    Med Microbiol Immunol; 2015 Feb; 204(1):57-68. PubMed ID: 25557605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in renal pre-dialysis and dialysis patients.
    Gilbert CL; Stek JE; Villa G; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Vaccine; 2014 Nov; 32(48):6521-6. PubMed ID: 25252192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and the preS2.
    Corradi MP; Tata C; Marchegiano P; Villa E; De Palma M; Trianni G; Fuiano L; Rompianesi P; Scacchetti T
    Arch Virol Suppl; 1992; 4():147-53. PubMed ID: 1450683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The impact of hepatitis B vaccination in Italy and the advent of novel recombinant vaccines containing pre-S1 and pre-S2].
    Romanò L; Biffi R; Bianchi S; Zanetti A
    Ann Ig; 2002; 14(3 Suppl 3):19-25. PubMed ID: 12389407
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.